Pension Fund ABP Settles With Merck In Securities Class Action
HEERLEN, Netherlands and AMSTERDAM, Feb. 14, 2013 /PRNewswire/ -- The Dutch pension fund Stichting Pensioenfonds ABP ("ABP"), together with three co-lead plaintiffs, has reached a settlement with Merck and certain of its current and former officers and directors, whereby Merck will pay $215 million to resolve a five-year-old securities class action against all of the Merck defendants. This settlement is part of a $688 million total settlement that Merck agreed to with plaintiffs in two class actions that were combined for trial: Merck & Co., Inc. Vytorin/Zetia Securities Litigation; and Schering-Plough Corporation/Enhance Securities Litigation.
The Merck Vytorin class action, filed in 2008, is pending before Judge Dennis M. Cavanaugh in U.S. District Court for the District of New Jersey. The settlement comes three weeks before a scheduled trial date of March 4. ABP, International Fund Management SA (part of the Deka Bank Group), the Jacksonville Police and Fire Retirement System, and the General Retirement System of the City of Detroit are the four institutional investor lead plaintiffs in the class action. The Merck Vytorin class action settlement covers all investors who purchased Merck stock or options between December 6, 2006 and March 28, 2008.
ABP's settlement stems from claims that Merck delayed disclosing for two years results of a clinical trial called ENHANCE - which indicated that Merck's anti-cholesterol drug Vytorin had no statistical advantage in treating atherosclerosis when compared to a generic statin drug, simvastatin. Merck investors alleged that the delay caused a substantial drop in the value of their shares when results of the study were published in 2008.
Merck has denied and continues to deny these claims, contending that the company and its officers acted responsibly in connection with the ENHANCE study. The settlement is subject to approval by Judge Cavanaugh.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV